Amivantamab Plus Chemo Extends Time to Treatment Discontinuation, Subsequent Therapy in EGFR Exon 20+ NSCLC
Patients with EGFR exon 20 insertion–mutated NSCLC treated with amivantamab plus chemotherapy experienced an extension in the time to treatment discontinuation and subsequent therapy.